PPC patients were more likely to be platinum resistant at 6 months and had significantly impaired PFS and OS. After multivariate analysis, PPC was independently associated with a worse prognosis for both survival endpoints. PPC was associated with a similar initial response but a higher rate of ...
Similarly, no patient who received more than three intervening nonplatinum treatments responded to additional platinum therapy (0/10). Our small retrospective series suggest that the platinum-resistant category is heterogenous and includes patients who may respond to retreatment with platinum-based agents...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
Inducing cell necrosis is a strategy to heighten the platinum sensitivity of tumor cells. Treatment with inhibitors of “inhibitors of apoptotic proteins” (IAPs) combined with caspase inhibitors selectively triggers TNFα- and RIPK3-dependent cell death in various ovarian cancer-resistant cell lines ...
While progression-free survival nearly doubled with bevacizumab, there was no measurable change in overall survival. Many patients who were symptomatic saw resolution of their symptoms in a significant way, notes Coleman. Improvement of symptoms, coupled with the limited number of options for this ...
Platinum resistant recurrence score The ROC curve for the Platinum Resistant Recurrence Score showed good accuracy, with an AUC of 0.73 (95% CI [0.64, 0.81]) (Fig. 2). A calibration analysis of the Platinum Resistant Recurrence Score was also performed, considering, for each patient, the prob...
作者: Amber Klein a,Xiaoying He a,Maria Roche a,Allison Mallett a,Linda Duska b,Jeffrey G. Supko a,Michael V. Seiden a 展开 摘要: Women with ovarian cancer who experience disease progression during or within 6 months of first-line treatment with platinum-based anticancer drugs are ...
In patients with platinum-resistant ovarian cancer, the randomized phase 3 AURELIA trial, demonstrated for the first time an improvement of progression-free survival (PFS) incorporating bevacizumab, a VEGF-inhibitor, to single-agent chemotherapy selected by investigator's choice (weekly paclitaxel, ...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), trea
Some studies have concentrated on the differences in clinical characteristics, such as tumor markers CA125 and HE4, between platinum-resistant and platinum-sensitive patients to seek clinical characteristics with predictive value [3]. These indicators can usually be obtained through routine examination ...